<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058057</url>
  </required_header>
  <id_info>
    <org_study_id>KC EK-150/08</org_study_id>
    <nct_id>NCT01058057</nct_id>
  </id_info>
  <brief_title>Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention (PCI) Study 2</brief_title>
  <acronym>TIPS-2</acronym>
  <official_title>Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Motol</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates potential protective effect of atorvastatin pre-treatment in patient
      with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) on
      chronic statin therapy. Patients are randomized into two groups: atorvastatin pre-treatment
      group (80mg atorvastatin seven days before PCI) and control group (PCI without atorvastatin
      pretreatment, chronic statin treatment). Endpoint is myocardial infarction measured by
      troponin I and creatine kinase myocardial band.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized study investigates potential protective effect of high dose atorvastatin
      pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary
      intervention (PCI) and chronic statin therapy.

      Two arms:

        1. atorvastatin pre-treatment group (80mg atorvastatin for seven days)

        2. control group (without atorvastatin pre-treatment, chronic statin treatment)

      Primary endpoint:

      Periprocedural myocardial infarction measured by troponin I level (time frame 24 hours)

      Secondary endpoint:

      Periprocedural myocardial infarction measured by creatine kinase myocardial band (time frame
      24 hours)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>periprocedural myocardial infarction measured by troponin I level</measure>
    <time_frame>24 hours after PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>periprocedural myocardial infarction measured by creatinine kinase myocardial band</measure>
    <time_frame>24 hours after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Angioplasty</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 80mg seven days pre-treatment before PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>atorvastatin 80mg p.o. daily seven days before PCI</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Torvacard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for percutaneous coronary intervention

          -  Informed consent

          -  Chronic statin therapy

        Exclusion Criteria:

          -  Acute coronary syndrome in last 14 days

          -  Renal insufficiency (creatinine more 150 umol/l)

          -  Diseases severely limiting prognosis

          -  Previous participation in this study

          -  Chronic occlusion of the coronary artery, bypass intervention, left main intervention

          -  Chronic statin treatment with atorvastatin 80mg daily and rosuvastatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Zemanek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, University Hospital Motol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josef Veselka, Prof., MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Carldiology, University Hospital Motol</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Zemanek, MD</last_name>
    <phone>+420608921</phone>
    <email>zejada@seznam.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dpt. of Cardiology, University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>15018</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Zemanek, MD</last_name>
      <phone>+420608921566</phone>
      <email>zejada@seznam.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <reference>
    <citation>Veselka J, Zemánek D, Hájek P, Malý M, Adlová R, Martinkovicová L, Tesar D. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. Am J Cardiol. 2009 Sep 1;104(5):630-3. doi: 10.1016/j.amjcard.2009.04.048. Epub 2009 Jun 24.</citation>
    <PMID>19699335</PMID>
  </reference>
  <reference>
    <citation>Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009 Aug 4;54(6):558-65. doi: 10.1016/j.jacc.2009.05.028. Epub 2009 Jul 2.</citation>
    <PMID>19643320</PMID>
  </reference>
  <reference>
    <citation>Mood GR, Bavry AA, Roukoz H, Bhatt DL. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol. 2007 Sep 15;100(6):919-23. Epub 2007 Jun 26.</citation>
    <PMID>17826370</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <last_update_submitted>February 2, 2010</last_update_submitted>
  <last_update_submitted_qc>February 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Anna Sediva, MD, PhD</name_title>
    <organization>University Hospital Motol</organization>
  </responsible_party>
  <keyword>atorvastatin</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>periprocedural myocardial infarction</keyword>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

